Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease
Allogeneic hematopoietic stem cell transplantation is a curative treatment for numerous hematological malignancies. However, acute graft-versus-host disease (aGvHD) is a major complication affecting 40–70% of all transplant patients, whereby the earliest and most frequent presentation is in the skin...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-07-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.01485/full |
id |
doaj-b3bedf4b3dc346a59cb1cefd57a49f7d |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sadaf Atarod Sadaf Atarod Jean Norden Louis A. Bibby Anne Janin Philippe Ratajczak Clare Lendrem Kim F. Pearce Xiao-Nong Wang Steven O’Reilly Jacob M. Van Laar Matthew Collin Anne M. Dickinson Rachel E. Crossland |
spellingShingle |
Sadaf Atarod Sadaf Atarod Jean Norden Louis A. Bibby Anne Janin Philippe Ratajczak Clare Lendrem Kim F. Pearce Xiao-Nong Wang Steven O’Reilly Jacob M. Van Laar Matthew Collin Anne M. Dickinson Rachel E. Crossland Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease Frontiers in Immunology microRNA GvHD biomarker molecular profiling cutaneous |
author_facet |
Sadaf Atarod Sadaf Atarod Jean Norden Louis A. Bibby Anne Janin Philippe Ratajczak Clare Lendrem Kim F. Pearce Xiao-Nong Wang Steven O’Reilly Jacob M. Van Laar Matthew Collin Anne M. Dickinson Rachel E. Crossland |
author_sort |
Sadaf Atarod |
title |
Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease |
title_short |
Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease |
title_full |
Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease |
title_fullStr |
Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease |
title_full_unstemmed |
Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease |
title_sort |
differential microrna expression levels in cutaneous acute graft-versus-host disease |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2018-07-01 |
description |
Allogeneic hematopoietic stem cell transplantation is a curative treatment for numerous hematological malignancies. However, acute graft-versus-host disease (aGvHD) is a major complication affecting 40–70% of all transplant patients, whereby the earliest and most frequent presentation is in the skin. MicroRNAs play a role in varied biological process and have been reported as potential biomarkers for aGvHD. More recently, microRNAs have received added attention as circulatory biomarkers that can be detected in biofluids. In this study, we performed global microRNA expression profiling using a discovery cohort of diagnostic cutaneous aGvHD biopsies (n = 5, stages 1–3) and healthy volunteers (n = 4), in order to identify a signature list of microRNAs that could be used as diagnostic biomarkers for cutaneous aGvHD. Candidate microRNAs (n = 8) were then further investigated in a validation cohort of post-HSCT skin biopsies (n = 17), pre-HSCT skin biopsies (n = 6) and normal controls (n = 6) for their association with aGvHD. Expression of let-7c (p = 0.014), miR-503-5p (p = 0.003), miR-365a-3p (p = 0.02), miR-34a-5p (p < 0.001) and miR-34a-3p (p = 0.006) were significantly differentially expressed between groups and significantly associated with survival outcome in post-HSCT patients (miR-503-5p ROC AUC = 0.83 p = 0.021, Log Rank p = 0.003; miR-34a-3p ROC AUC = 0.93, p = 0.003, Log Rank p = 0.004). There was no association with relapse. A statistical interaction between miR-34a-3p and miR-503-5p (p = 0.016) was diagnostic for aGvHD. Expression levels of the miR-34a-5p protein target p53 were assessed in the epidermis of the skin, and an inverse correlation was identified (r2 = 0.44, p = 0.039). Expression of the validated candidate microRNAs was also assessed at day 28 post-HSCT in the sera of transplant recipients, in order to investigate their potential as circulatory microRNA biomarkers. Expression of miR-503-5p (p = 0.001), miR-34a-5p (p = 0.005), and miR-34a-3p (p = 0.004) was significantly elevated in the sera of patients who developed aGvHD versus no-aGvHD (n = 30) and miR-503-5p was associated with overall survival (OS) (ROC AUC = 0.80, p = 0.04, Log Rank p = 0.041). In conclusion, this investigation reports that microRNA expression levels in clinical skin biopsies, obtained at the time of cutaneous aGvHD onset, show potential as diagnostic biomarkers for aGvHD and as predictive biomarkers for OS. In addition, the same microRNAs can be detected in the circulation and show predictive association with post-HSCT outcomes. |
topic |
microRNA GvHD biomarker molecular profiling cutaneous |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2018.01485/full |
work_keys_str_mv |
AT sadafatarod differentialmicrornaexpressionlevelsincutaneousacutegraftversushostdisease AT sadafatarod differentialmicrornaexpressionlevelsincutaneousacutegraftversushostdisease AT jeannorden differentialmicrornaexpressionlevelsincutaneousacutegraftversushostdisease AT louisabibby differentialmicrornaexpressionlevelsincutaneousacutegraftversushostdisease AT annejanin differentialmicrornaexpressionlevelsincutaneousacutegraftversushostdisease AT philipperatajczak differentialmicrornaexpressionlevelsincutaneousacutegraftversushostdisease AT clarelendrem differentialmicrornaexpressionlevelsincutaneousacutegraftversushostdisease AT kimfpearce differentialmicrornaexpressionlevelsincutaneousacutegraftversushostdisease AT xiaonongwang differentialmicrornaexpressionlevelsincutaneousacutegraftversushostdisease AT stevenoreilly differentialmicrornaexpressionlevelsincutaneousacutegraftversushostdisease AT jacobmvanlaar differentialmicrornaexpressionlevelsincutaneousacutegraftversushostdisease AT matthewcollin differentialmicrornaexpressionlevelsincutaneousacutegraftversushostdisease AT annemdickinson differentialmicrornaexpressionlevelsincutaneousacutegraftversushostdisease AT rachelecrossland differentialmicrornaexpressionlevelsincutaneousacutegraftversushostdisease |
_version_ |
1725951032090951680 |
spelling |
doaj-b3bedf4b3dc346a59cb1cefd57a49f7d2020-11-24T21:33:58ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-07-01910.3389/fimmu.2018.01485389480Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host DiseaseSadaf Atarod0Sadaf Atarod1Jean Norden2Louis A. Bibby3Anne Janin4Philippe Ratajczak5Clare Lendrem6Kim F. Pearce7Xiao-Nong Wang8Steven O’Reilly9Jacob M. Van Laar10Matthew Collin11Anne M. Dickinson12Rachel E. Crossland13Haematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United KingdomNewborn Medicine, Brigham and Women’s Hospital, Harvard University, Boston, MA, United StatesHaematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United KingdomHaematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United KingdomUniversité Paris Diderot, INSERM, UMR_S1165, Paris, FranceUniversité Paris Diderot, INSERM, UMR_S1165, Paris, FranceHaematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United KingdomHaematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United KingdomHaematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United KingdomFaculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United KingdomDepartment of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht University, Utrecht, NetherlandsHaematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United KingdomHaematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United KingdomHaematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United KingdomAllogeneic hematopoietic stem cell transplantation is a curative treatment for numerous hematological malignancies. However, acute graft-versus-host disease (aGvHD) is a major complication affecting 40–70% of all transplant patients, whereby the earliest and most frequent presentation is in the skin. MicroRNAs play a role in varied biological process and have been reported as potential biomarkers for aGvHD. More recently, microRNAs have received added attention as circulatory biomarkers that can be detected in biofluids. In this study, we performed global microRNA expression profiling using a discovery cohort of diagnostic cutaneous aGvHD biopsies (n = 5, stages 1–3) and healthy volunteers (n = 4), in order to identify a signature list of microRNAs that could be used as diagnostic biomarkers for cutaneous aGvHD. Candidate microRNAs (n = 8) were then further investigated in a validation cohort of post-HSCT skin biopsies (n = 17), pre-HSCT skin biopsies (n = 6) and normal controls (n = 6) for their association with aGvHD. Expression of let-7c (p = 0.014), miR-503-5p (p = 0.003), miR-365a-3p (p = 0.02), miR-34a-5p (p < 0.001) and miR-34a-3p (p = 0.006) were significantly differentially expressed between groups and significantly associated with survival outcome in post-HSCT patients (miR-503-5p ROC AUC = 0.83 p = 0.021, Log Rank p = 0.003; miR-34a-3p ROC AUC = 0.93, p = 0.003, Log Rank p = 0.004). There was no association with relapse. A statistical interaction between miR-34a-3p and miR-503-5p (p = 0.016) was diagnostic for aGvHD. Expression levels of the miR-34a-5p protein target p53 were assessed in the epidermis of the skin, and an inverse correlation was identified (r2 = 0.44, p = 0.039). Expression of the validated candidate microRNAs was also assessed at day 28 post-HSCT in the sera of transplant recipients, in order to investigate their potential as circulatory microRNA biomarkers. Expression of miR-503-5p (p = 0.001), miR-34a-5p (p = 0.005), and miR-34a-3p (p = 0.004) was significantly elevated in the sera of patients who developed aGvHD versus no-aGvHD (n = 30) and miR-503-5p was associated with overall survival (OS) (ROC AUC = 0.80, p = 0.04, Log Rank p = 0.041). In conclusion, this investigation reports that microRNA expression levels in clinical skin biopsies, obtained at the time of cutaneous aGvHD onset, show potential as diagnostic biomarkers for aGvHD and as predictive biomarkers for OS. In addition, the same microRNAs can be detected in the circulation and show predictive association with post-HSCT outcomes.https://www.frontiersin.org/article/10.3389/fimmu.2018.01485/fullmicroRNAGvHDbiomarkermolecular profilingcutaneous |